arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Humacyte, Inc.

HUMA
$0.39 ▼ -0.06 (-12.53%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
27 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Humacyte, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $91.3M
Dividend Yield —
Revenue Growth 34.9% ↗
Op. Margin —
ROIC -31.6% ↗
FCF / Share $-0.09 ↗
Trailing P/E —
Price / Book 3.5x
FCF Yield —
Debt / Equity 1.16
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$406.00K
↑ +34.9% —
Net Income Profit after all expenses
$-17.62M
— 0.0% —
FCF / Share Free cash flow per share
$-0.09
↑ +25.9% —
Long-Term Debt Long-term obligations
$36.32M
↑ +1.3% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health ↑
2
Cash Quality ↓
90

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters